NHS England’s rollout remains limited and uneven, despite a long-term plan, as many eligible patients still cannot access treatment through the NHS while private use rises.

NHS England projects the first-year uptake could occupy roughly a significant share of GP appointments, underscoring capacity challenges.

The new GP contract includes incentives eight months after the mass rollout began, but GPs are concerned about workload and patient access.

GLP‑1 injections such as Mounjaro, Wegovy, and Ozempic work by suppressing appetite and slowing digestion, with potential side effects like vomiting and stomach cramps.

The secretary says the shift aims to align access with need, reduce private reliance, and support prevention alongside treatment.

Obesity Health Alliance, BMA, and Royal College of GPs caution that sustained support, broader public health actions, and careful workload management are essential as access expands.

There are concerns that if all eligible patients sought treatment in the first year, it could overwhelm primary care, with projections suggesting a sizable impact on GP appointments.

Britain is seeing a large private uptake of weight‑loss injections, with about 2.4 million people paying privately, while the NHS is rolling out the drugs in a phased, targeted way that currently prioritizes the most severely overweight patients with additional health problems.

Medical groups acknowledge capacity and workload constraints, with eligibility decisions and rollout led at the national level by safety, effectiveness, and service capacity considerations.

Health advocates warn the NHS may lack sufficient capacity to expand access without extra resources, stressing the need for sustained lifestyle interventions alongside treatment.

Experts see potential for community pharmacies to play a larger role in facilitating access and wraparound care as part of a broader weight‑management strategy.

The Health Secretary argues access should be based on medical need rather than ability to pay, criticizing private‑sector prescribing and rogue practices outside the NHS.